XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 3 - Revenue
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

NOTE 3. REVENUE

 

Revenue recognition

Our revenue is comprised of product, engineering services and repair services. All revenue is recognized when the Company satisfies its performance obligation(s) under the contract by transferring the promised product or service to our customer either when (or as) our customer obtains control of the product or service, with the majority of our revenue being recognized over time including goods produced under contract manufacturing agreements and services revenue. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer. A contract’s transaction price is allocated to each distinct performance obligation. The majority of our contracts have a single performance obligation, as the promise to transfer products or services is not separately identifiable from other promises in the contract and, therefore, not distinct.

 

Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products or providing services. As such, revenue is recorded net of returns, allowances and customer discounts. Sales, value add, and other taxes collected from customers and remitted to governmental authorities are accounted for on a net (excluded from revenues) basis. Shipping and handling costs are included in cost of goods sold.

 

The majority of our revenue is derived from the transfer of goods produced under contract manufacturing agreements which have no alternative use and we have an enforceable right to payment for our performance completed to date. Our performance obligations within our contract manufacturing agreements are generally satisfied over time as the goods are produced based on customer specifications and we have an enforceable right to payment for the goods produced. If these requirements are not met, the revenue is recognized at a point in time, generally upon shipment. Revenue under contract manufacturing agreements that was recognized over time accounted for approximately 74% of our revenue for both the three and nine months ended September 30, 2022 and 82% and 80% of our revenue for the three and nine months ended September 30, 2021, respectively. Revenues under these agreements are generally recognized over time using an input measure based upon the proportion of actual costs incurred.

 

Accounting for contract manufacturing agreements involves the use of various techniques to estimate total revenue and costs. We estimate profit on these agreements as the difference between total estimated revenue and expected costs to complete the performance obligation within the terms of the agreement and recognize the respective profit as the goods are produced. The estimates to determine the profit earned on the performance obligation are based on anticipated selling prices and historical cost of goods sold and represent our best judgement at the time. Changes in judgements on these above estimates could impact the timing and amount of revenue recognized with a resulting impact on the timing and amount of associated profit.

 

On occasion our customers provide materials to be used in the manufacturing process and the fair value of the materials is included in revenue as noncash consideration at the point in time when the manufacturing process commences along with the same corresponding amount recorded as cost of goods sold. The inclusion of noncash consideration has no impact on overall profitability.

 

 

Contract Assets

Contract assets, recorded as such in the Condensed Consolidated Balance Sheets, consist of unbilled amounts related to revenue recognized over time. Significant changes in the contract assets balance during the nine months ended September 30, 2022 was as follows (in thousands):

 

Balance outstanding at December 31, 2021

  $ 8,698  

Increase (decrease) attributed to:

       

Amounts transferred over time to contract assets

    72,536  

Amounts invoiced during the period

    (71,348 )

Balance outstanding at September 30, 2022

  $ 9,886  

 

We expect substantially all the remaining performance obligations for the contract assets recorded as of September 30, 2022 to be transferred to receivables within 90 days, with the majority of any remaining amounts to be transferred within 180 days. We bill our customers upon shipment with payment terms of up to 120 days.

 

The following tables summarize our net sales by timing of transfer of goods and services by market:

 

   

Three Months Ended September 30, 2022

 
   

Product/ Service

Transferred Over

Time

   

Product

Transferred at

Point in Time

   

Noncash

Consideration

   

Total Net Sales by

Market

 

Medical

  $ 14,753     $ 5,366     $ 420     $ 20,539  

Industrial

    8,104       2,314       420       10,838  

Aerospace and Defense

    3,202       493       204       3,899  

Total net sales

  $ 26,059     $ 8,173     $ 1,044     $ 35,276  

 

 

   

Nine Months Ended September 30, 2022

 
   

Product/ Service

Transferred Over

Time

   

Product

Transferred at

Point in Time

   

Noncash

Consideration

   

Total Net Sales by

Market

 

Medical

  $ 37,725     $ 15,044     $ 1,574     $ 54,343  

Industrial

    21,563       6,301       1,095       28,959  

Aerospace and Defense

    13,248       1,254       701       15,203  

Total net sales

  $ 72,536     $ 22,599     $ 3,370     $ 98,505  

 

 

   

Three Months Ended September 30, 2021

 
   

Product/ Service

Transferred Over

Time

   

Product

Transferred at

Point in Time

   

Noncash

Consideration

   

Total Net Sales by

Market

 

Medical

  $ 13,762     $ 2,933     $ 282     $ 16,977  

Industrial

    7,468       1,757       158       9,383  

Aerospace and Defense

    2,883       144       65       3,092  

Total net sales

  $ 24,113     $ 4,834     $ 505     $ 29,452  

 

 

   

Nine Months Ended September 30, 2021

 
   

Product/ Service

Transferred Over

Time

   

Product

Transferred at

Point in Time

   

Noncash

Consideration

   

Total Net Sales by

Market

   

Medical

  $ 35,497     $ 8,876     $ 1,017     $ 45,390  

Industrial

    20,385       4,832       560       25,777  

Aerospace and Defense

    9,685       527       327       10,539  

Total net sales

  $ 65,567     $ 14,235     $ 1,904     $ 81,706